Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,620.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $12.00, for a total transaction of $19,620.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 15.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Scott Bizily also recently made the following trade(s):

• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total value of $19,947.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Trading Up 13.9%

FDMT opened at $16.76 on Thursday. The stock’s fifty day moving average is $11.33 and its two-hundred day moving average is $10.03. The company has a market capitalization of $925.82 million, a P/E ratio of -6.37 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $16.93. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. Analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the stock. Persistent Asset Partners Ltd purchased a new position in 4D Molecular Therapeutics in the second quarter valued at about $1,936,000. Dimensional Fund Advisors LP raised its holdings in 4D Molecular Therapeutics by 77.3% in the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock worth $4,863,000 after purchasing an additional 227,982 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at about $1,216,000. Perigon Wealth Management LLC purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at about $1,944,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $656,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on FDMT. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Finally, Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.